Options Brief: Celsion Corporation (CLSN)

Shares of Celsion Corporation CLSN are higher on the session by 9.43%, trading at $2.67. Overall put volume is now running at 107.14x the daily average, with 0% of all puts traded being purchases on the offer. 3,000 contracts have traded on the session so far. Celsion Corporation is an oncology drug development company focused on improving treatment for those suffering with aggressive and difficult to treat forms of cancer. Its lead product ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer and a Phase II study for recurrent chest wall breast cancer.